Chiasma Inc. (CHMA) Trading Down 3.5%
Chiasma Inc. (NASDAQ:CHMA)’s share price dropped 3.5% on Friday . The stock traded as low as $2.72 and last traded at $2.74, with a volume of 55,732 shares changing hands. The stock had previously closed at $2.84.
CHMA has been the subject of several research reports. Cowen and Company reaffirmed a “hold” rating on shares of Chiasma in a research report on Friday, May 13th. Zacks Investment Research downgraded Chiasma from a “hold” rating to a “sell” rating in a research report on Monday, April 4th. Barclays PLC reissued a “buy” rating and set a $40.00 price objective on shares of Chiasma in a research report on Thursday, March 31st. Oppenheimer Holdings Inc. reissued an “outperform” rating and set a $9.00 price objective (down from $43.00) on shares of Chiasma in a research report on Monday, April 18th. Finally, William Blair downgraded Chiasma from an “outperform” rating to a “market perform” rating in a research report on Monday, April 18th. One analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company’s stock. Chiasma presently has a consensus rating of “Hold” and a consensus target price of $19.70.
The company’s market capitalization is $66.58 million. The company has a 50-day moving average price of $2.86 and a 200 day moving average price of $6.94.
Chiasma (NASDAQ:CHMA) last released its earnings results on Wednesday, May 11th. The company reported ($0.71) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by $0.08. On average, analysts predict that Chiasma Inc. will post ($2.66) EPS for the current year.
Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.